InMed Pharmaceuticals Inc

Company Profile

InMed Pharmaceuticals Inc had its IPO on 2020-11-12 under the ticker symbol INM.

The company operates in the Healthcare sector and Biotechnology industry. InMed Pharmaceuticals Inc has a staff strength of 13 employees.

Stock update

Shares of InMed Pharmaceuticals Inc opened at $1 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.89 - $1, and closed at $0.94.

This is a -2.76% slip from the previous day's closing price.

A total volume of 40,247 shares were traded at the close of the day’s session.

In the last one week, shares of InMed Pharmaceuticals Inc have increased by +14.88%.

InMed Pharmaceuticals Inc's Key Ratios

InMed Pharmaceuticals Inc has a market cap of $2.75 million, indicating a price to book ratio of 0.1975 and a price to sales ratio of 1.4334.

In the last 12-months InMed Pharmaceuticals Inc’s revenue was $2.34 million with a gross profit of $543546 and an EBITDA of $-10507133. The EBITDA ratio measures InMed Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, InMed Pharmaceuticals Inc’s operating margin was -457.83% while its return on assets stood at -44.31% with a return of equity of -133.02%.

In Q1, InMed Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 234%.

InMed Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-17.16 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into InMed Pharmaceuticals Inc’s profitability.

InMed Pharmaceuticals Inc stock is trading at a EV to sales ratio of 1.4657 and a EV to EBITDA ratio of 0.3487. Its price to sales ratio in the trailing 12-months stood at 1.4334.

InMed Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$14.73 million

Total Liabilities

$2.27 million

Operating Cash Flow

$0

Capital Expenditure

$128198

Dividend Payout Ratio

0%

InMed Pharmaceuticals Inc ended 2024 with $14.73 million in total assets and $0 in total liabilities. Its intangible assets were valued at $14.73 million while shareholder equity stood at $12.39 million.

InMed Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $2.27 million in other current liabilities, 77620252.00 in common stock, $-101061818.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.60 million and cash and short-term investments were $9.60 million. The company’s total short-term debt was $423,574 while long-term debt stood at $0.

InMed Pharmaceuticals Inc’s total current assets stands at $11.84 million while long-term investments were $0 and short-term investments were $43.06 million. Its net receivables were $170299.00 compared to accounts payable of $737501.00 and inventory worth $1.33 million.

In 2024, InMed Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $128198.

Comparatively, InMed Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.94

52-Week High

$12

52-Week Low

$0.78

Analyst Target Price

$

InMed Pharmaceuticals Inc stock is currently trading at $0.94 per share. It touched a 52-week high of $12 and a 52-week low of $12. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.95 and 200-day moving average was $1.38 The short ratio stood at 0.29 indicating a short percent outstanding of 0%.

Around 15.2% of the company’s stock are held by insiders while 303.3% are held by institutions.